HINDUSTAN BIO SCIENCES LTD. is a IT - Software company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 | 1 | 1 | 1 |
| EBITDA (ex other income) | (1) | (0) | 0 | 0 | (0) |
| margin % | (127.9) | (3.1) | 3.9 | 12.3 | (7.9) |
| Owners' profit | (1) | (0) | 0 | 0 | (0) |
| EPS, as reported (₹) | (0.50) | (0.04) | 0.06 | 0.10 | 0.08 |
| ROE % · ROCE % | (65.8) · (27.4) | (5.4) · (1.8) | 7.2 · 1.7 | 11.1 · 2.9 | (9.6) · (2.5) |
| Debt / equity (x) | 2.75 | 3.29 | 3.18 | 2.77 | 2.84 |
| Cash from operations | (0) | (0) | (0) | 0 | 0 |
| Capex | (0) | 0 | 0 | 0 | 0 |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | (0) | (0) | 0 | 0 | (0) | 0 | (0) |
| Net profit | 0 | (0) | (0) | 0 | 0 | (0) | 0 | (0) |
| EPS (₹) | 0.08 | (0.05) | (0.40) | 0.11 | 0.01 | 0.06 | 0.08 | 0.11 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| ORACLE FIN SERV SOFT LTD. | 1,02,338 | 30.0 | 13.08 | 26.9 | 33.7 | 43.2 | 9.0 | 62.5 |
| TANLA PLATFORMS LIMITED | 6,684 | 12.5 | 2.69 | 7.8 | 20.5 | 25.0 | 13.5 | 17.6 |
| C.E. INFO SYSTEMS LIMITED | 5,056 | 36.8 | 5.59 | 21.9 | 14.8 | 21.3 | — | 54.2 |
| CAPILLARY TECHNO INDIA L | 3,656 | 86.5 | 3.57 | 27.9 | 5.1 | 4.9 | — | 4.9 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · 34th AGM on Sep 30; book closure Sep 24-30; e-voting Sep 27-29 | compliance | minimal | — | — |
| 3 Sept 2026 · AGM notice with capital reduction to write off losses | results | high | — | — |
| 3 Sept 2026 · 34th Annual Report and AGM Notice filed; share capital reduction proposed | board shareholder meetings | medium | — | — |
| 31 Aug 2026 · Board approves capital reduction and share consolidation | corporate actions | high | — | — |
| 26 Aug 2026 · Board meet on Aug 31 to consider share capital reorganization scheme | strategic transactions | medium | — | — |
| 3 Aug 2026 · Hindustan Bio Sciences Q1 FY27 revenue nil, loss widens to Rs 11.29L | compliance | minimal | — | — |
| 31 Jul 2026 · Hindustan Bio Sciences Q1 FY27: Zero revenue, Rs 11.29 lakh loss | results | high | — | — |
| 31 Jul 2026 · Hindustan Bio Sciences Q1 loss widens, revenue drops to zero | results | high | — | — |
| 22 Jul 2026 · Board Meeting on 31 July 2026 to consider Q1 FY27 results | results | low | — | — |
| 9 Jul 2026 · RTA confirms no share demat requests in Q1 FY27 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| TECHNVISION VENTURES LTD. | 2,991 | 344.1 | 199.35 | 399.6 | 1.4 | 5.5 | 25.5 | (3.0) |
| RAMCO SYSTEMS LTD. | 2,239 | 53.6 | 6.33 | 14.7 | 11.9 | 11.0 | 2.3 | 16.0 |
| Mobavenue AI Tech Limited | 2,135 | 16.9 | 23.58 | 44.6 | 32.4 | 30.8 | — | 21.8 |
| NUCLEUS SOFTWARE EXPORTS | 1,828 | 17.3 | 2.01 | 10.4 | 12.9 | 15.2 | 11.3 | 16.9 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.9 | 19.0 | 30 of 41 | 28% |
| P/B | 10.0 | 1.6 | 35 of 38 | 8% |
| ROCE | (2.5) | 4.9 | 35 of 43 | 19% |
| ROE | (9.6) | 3.5 | 37 of 42 | 12% |
| Debt / Equity | 2.8 | 0.0 | 42 of 42 | 0% |
| Revenue growth | (100.0) | 9.7 | 31 of 33 | 0% |
| Profit growth | (208.0) | (12.0) | 35 of 41 | 15% |
| Market cap | 8 | 38 | 37 of 44 | 16% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
